IDYA News and Press, IDEAYA Biosciences Inc. From 05/22/23

IDEAYA Announces IND Clearance Enabling Phase 1/2 Clinical Trial for Combination of IDE397 and AMG 193 in MTAP-Deletion Solid Tumors PR Newswire IDE397 (MAT2A) and AMG 193 (PRMT5) combination being evaluated in an Amgen-sponsored Phase 1/2 clinical trial in MTAP-deletion solid...

IDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer to Support Registrational Trial Evaluating Darovasertib and Crizotinib Combination in First-Line Metastatic Uveal Melanoma PR Newswire Amended clinical trial collaboration and supply agreements with ...

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is the focus of IBN's latest stock spotlight. The company's shares have moved -4.37% on the day to $21.46. IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted t...

2023-05-09 08:47:22 ET IDEAYA Biosciences press release ( NASDAQ: IDYA ): Q1 GAAP EPS of -$0.49 beats by $0.03 . Revenue of $7.88M (-30.6% Y/Y) beats by $2.5M . For further details see: IDEAYA Biosciences GAAP EPS of -$0.49 beats by $0.03, revenue of $7.8...

IDEAYA Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update PR Newswire Strong balance sheet of $351.2 million of cash, cash equivalents and marketable securities as of March 31, 2023 supplemented by $188.7 million estimated n...

IDEAYA Biosciences to Participate in Upcoming May 2023 Investor Relations Event PR Newswire SOUTH SAN FRANCISCO, Calif. , May 1, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and dev...

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire SOUTH SAN FRANCISCO, Calif. , April 27, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the clos...

2023-04-25 09:17:44 ET IDEAYA Biosciences ( NASDAQ: IDYA ) prices an underwritten public offering of ~7.44M shares and pre-funded warrants to purchase ~2.02M shares. The shares of common stock are being sold at a public offering price of $18.50 per share and the pre-funde...

IDEAYA Announces Pricing of Public Offering PR Newswire SOUTH SAN FRANCISCO, Calif. , April 24, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of an underwritten public offering of common stock and pre-funded warrants. IDE...

2023-04-24 16:32:22 ET IDEAYA Biosciences ( NASDAQ: IDYA ) on Monday announced a proposed public stock offering of up to $150M. IDYA also said it intends to grant the underwriters a 30-day option to purchase up to $22.5M of shares of its common stock. The announcement ...